Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Chronic lymphocytic leukemia
Pirtobrutinib Reaches 93% ORR and 93% 24-Month PFS in Frontline CLL/SLL
Pirtobrutinib is a selective, reversible, non-covalent BTK inhibitor evaluated as continuous monotherapy in treatment-naïve CLL/SLL using pooled pirtobrutinib arms from BRUIN CLL-313 and BRUIN CLL-314 (n=253; safety…
- Trial result
Neuroendocrine and adrenal tumors
Cabozantinib (multi-kinase VEGFR/MET/AXL inhibitor) cuts progression risk in functional vs non-functional NET in CABINET
Cabozantinib (CABO) is an oral multi-target tyrosine kinase inhibitor (notably VEGFR2, MET, AXL) evaluated in the Phase 3 CABINET trial (NCT03375320) in progressive, previously treated advanced extrapancreatic NET…
NCT03375320 - Trial result
Neuroendocrine and adrenal tumors
Lu-177 Edotreotide Preserves QoL Better Than Everolimus in GEP-NETs
Lutetium Lu-177 edotreotide is an SSTR-targeted peptide receptor radionuclide therapy compared with everolimus in the Phase 3 COMPETE trial (NCT03049189) for grade 1/2 well-differentiated gastroenteropancreatic NETs.…
NCT03049189 - Trial result
Neuroendocrine and adrenal tumors
[212Pb]VMT-α-NET Shows 39% ORR With Low Early Myelosuppression in NETs
[212Pb]VMT-α-NET is an SSTR2-targeted alpha-particle radiopharmaceutical being dose-found in a Phase 1/2a Bayesian escalation trial for unresectable/metastatic well-differentiated SSTR2+ NETs after ≥1 prior systemic…
NCT05636618 - Trial result Spotlight
Liver and bile duct cancer
Nivolumab+Ipilimumab (PD-1+CTLA-4) Sustains OS Benefit in 1L Unresectable HCC; Deep Responses Track With Long Survival
Nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) was tested vs lenvatinib/sorafenib (TKI SOC options) in the Phase 3 CheckMate-9DW first-line unresectable HCC trial (NCT04039607; n=668), with nivolumab…
NCT04039607 - Trial result
Liver and bile duct cancer
Early sofosbuvir-based DAAs + atezolizumab/bevacizumab boosts circulating T-cells but yields 0% ORR in HCV-HCC
In the open-label, single-arm Phase IV NCT05717400 trial, patients with HCV-associated advanced HCC received first-line atezolizumab (PD-L1) plus bevacizumab (VEGF) alongside early direct-acting antivirals…
NCT05717400 - Trial result
Liver and bile duct cancer
Tegavivint (TBL1→nuclear β-catenin degradation) shows 22% ORR in Wnt-mutant 2L/3L aHCC
Tegavivint is a first-in-class IV small molecule that binds TBL1 to disrupt the TBL1/β-catenin complex, driving selective degradation of nuclear β-catenin (downstream Wnt/β-catenin inhibition). In this multicenter…
NCT05797805 - Trial result
Lymphoma
Liso-cel (CD19 CAR-T) delivers 88% ORR/80% CR in real-world R/R mantle cell lymphoma
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed CAR-T product with a defined CD4:CD8 composition and 4-1BB costimulation, evaluated here in a US CIBMTR retrospective real-world cohort of commercial…
- Trial result Spotlight
Uterine (endometrial) cancer
Puxitatug Samrotecan B7-H4 ADC Posts 48% ORR in Relapsed Endometrial Cancer
Puxitatug samrotecan (AZD8205) is a B7-H4–directed topoisomerase I ADC tested in the Phase 1/2a BLUESTAR expansion (NCT05123482) in B7-H4-positive relapsed/metastatic endometrial or ovarian cancer after…
NCT05123482 - Trial result
Uterine (endometrial) cancer
Atezolizumab (PD-L1) + bevacizumab (VEGF) posts 33.9% ORR in platinum-pretreated recurrent/metastatic endometrial cancer
Atezolizumab is an anti–PD-L1 immune checkpoint inhibitor and bevacizumab is an anti-VEGF monoclonal antibody; this Phase 2 open-label, multicenter, single-arm study treated ICI-naïve recurrent/metastatic endometrial…
NCT03526432 - Trial result
Uterine (endometrial) cancer
Dostarlimab (PD-1) + carboplatin/paclitaxel shows 57.9% 4-year PFS and ~54% “cure fraction” in dMMR/MSI-H endometrial cancer (RUBY)
Dostarlimab (Jemperli) is an anti–PD-1 monoclonal antibody combined with carboplatin–paclitaxel (CP) as first-line therapy for primary advanced or recurrent dMMR/MSI-H endometrial cancer in the Phase 3, randomized…
NCT03981796 - Trial result
Uterine (endometrial) cancer
Pembrolizumab (PD-1) + carboplatin/paclitaxel sustains 48-mo OS gains in dMMR endometrial cancer
Pembrolizumab is an anti–PD-1 checkpoint inhibitor added to carboplatin/paclitaxel (CP) induction (6 cycles Q3W) followed by pembrolizumab maintenance (Q6W up to 24 months) in the Phase 3, randomized…
NCT03914612 - Trial result
Uterine (endometrial) cancer
Dostarlimab (PD-1) + Pelvic IMRT in MMR-D Endometrial Cancer: ctDNA Clears in Most, Flags Distant Relapse
D-RT (NCT04774419) is an investigator-initiated, single-arm Phase II study testing adjuvant dostarlimab (anti–PD-1 checkpoint inhibitor) given concurrently with standard pelvic IMRT after surgery in newly diagnosed…
NCT04774419 - Trial result Spotlight
Skin cancer (non-melanoma)
Cemiplimab (PD-1) + response-adapted definitive RT delivers 86% 18-mo EFS in unresectable LA cSCC (RAMPART)
Cemiplimab-rwlc is an anti–PD-1 monoclonal antibody; in RAMPART (Phase II, multicenter, single-arm; NCT05574101), it was given neoadjuvantly (2 doses then response-adapted), concurrently with definitive radiotherapy…
NCT05574101 - Trial result
Skin cancer (non-melanoma)
Cemiplimab (PD-1) Cuts Recurrence Risk in High-Risk Resected CSCC—Consistent Across Risk Features and RT Timing
Cemiplimab (Libtayo) is an anti–PD-1 antibody tested as adjuvant systemic therapy after surgery plus postoperative radiotherapy in the Phase 3, double-blind C-POST trial (NCT03969004). In this exploratory DFS update…
NCT03969004 - Trial result
Skin cancer (non-melanoma)
Neoadjuvant anti–PD-1 immunotherapy drives 54% pCR and improves 2-year EFS in resectable stage III–IV cSCC
In a single-institution retrospective series of resectable stage III/IV cutaneous squamous cell carcinoma treated 2010–2024 (n=300), neoadjuvant (NEO) anti–PD-1 immunotherapy (median 3 cycles) followed by surgery was…
NCT06568172 - Trial result
Skin cancer (non-melanoma)
Cosibelimab PD-L1 Delivers 50% ORR in Unresectable Locally Advanced cSCC
Cosibelimab is a high-affinity PD-L1 antibody evaluated at 800 mg IV every 2 weeks in the pivotal Phase 1 cutaneous SCC expansion cohort (NCT03212404). In unresectable locally advanced cSCC not amenable to curative…
NCT03212404 - Trial result
Brain and CNS tumors
Lu-177 dotatate PRRT (SSTR2-targeted) hits 69% PFS-6 in refractory intracranial meningioma; Ga-68 dotatate PET tracks response
[177Lu]Lu-DOTA-TATE (Lu-177 dotatate) is a somatostatin receptor 2 (SSTR2)–targeted peptide receptor radionuclide therapy (PRRT), paired here with exploratory [68Ga]Ga-DOTA-TATE PET as a functional imaging biomarker,…
NCT03971461 - Trial result
Sarcoma and GIST
RMS13 (NCT01871766) Response-Adapted Metastasis RT Shows Soft-Tissue “CR” Still Relapses in HR RMS
RMS13 is a Phase II prospective multicenter pediatric high-risk metastatic rhabdomyosarcoma study testing interval-compressed multiagent chemotherapy plus risk-adapted proton radiotherapy (RT) to primary tumor and…
- Trial result Spotlight
Lymphoma
Golcadomide (CC-99282) CELMoD + rituximab drives 97% ORR/78% CR in heavily pretreated R/R follicular lymphoma
Golcadomide (GOLCA; CC-99282) is an oral cereblon E3 ligase modulator (CELMoD) that degrades Ikaros/Aiolos to combine direct tumor cell killing with immunomodulatory effects; in the Phase 1/2 CC-99282-NHL-001 study…
NCT03930953 - Trial result
Lymphoma
Liso-cel (CD19 CAR-T) Drives 89% ctDNA-MRD Negativity in 3L+ R/R Follicular Lymphoma, Tracking with 36-mo PFS
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed CAR-T cell therapy; in this exploratory TRANSCEND FL (NCT04245839) analysis of third-line or later (3L+) relapsed/refractory follicular lymphoma,…
NCT04245839 - Trial result
Head and neck cancer
FMISO PET hypoxia imaging guides 30Gy chemoradiation with 97% 5-year OS in HPV+ OPC
Integrated analysis of three consecutive Phase II trials tested ^18F-fluoromisonidazole PET (FMISO PET) to stratify definitive chemoradiotherapy intensity in T0–3/N1–2c HPV+ oropharyngeal cancer (n=430; enrollment…
NCT06563479 - Trial result
Head and neck cancer
ICT (carboplatin/paclitaxel/cetuximab) + FMISO-PET Hypoxia Clearance Enables 30Gy De-escalation in T3–T4 HPV+ OPC
In this pilot study (NCT05491512), weekly induction chemotherapy with carboplatin (AUC2) + paclitaxel (90 mg/m²) + cetuximab (after 400 mg/m² load, then 250 mg/m² weekly) for 6 weeks was used to downstage very…
NCT05491512 - Trial result
Head and neck cancer
HB200 (HPV16 E6/E7 viral immunotherapy) + carbo/pac drives 88% deep responses and enables de-escalation in HPV16+ OPSCC
HB200 is an HPV16-directed arenavirus-based therapeutic vaccine regimen (HB201 and HB202 vectors encoding a non-oncogenic HPV16 E6/E7 fusion) given neoadjuvantly with carboplatin/paclitaxel in an…
NCT05108870 - Trial result
Colorectal cancer
Avelumab (PD-L1) + neoadjuvant chemoradiotherapy delivers 74.7% 4-year PFS in high-risk LARC (AVANA)
Avelumab is an anti–PD-L1 immune checkpoint inhibitor added to standard neoadjuvant long-course chemoradiotherapy (CTRT) for locally advanced rectal cancer, aiming to deepen response before surgery. In the…
NCT03854799 - Trial result
Colorectal cancer
Toripalimab (PD-1) + CAPOX iTNT, with SCRT, lifts complete response to 61% in high-risk pMMR LARC
TORCH-iTNT (NCT06281405) is a randomized Phase 2 study in pMMR/MSS locally advanced rectal cancer (T3–4/N+M0) comparing 6 cycles of CAPOX (capecitabine/oxaliplatin) + toripalimab (PD-1 inhibitor) alone (Group A) vs…
NCT06281405 - Trial result
Sarcoma and GIST
Pom/Nivo (IMiD + PD-1 blockade) hits 100% response in evaluable Kaposi sarcoma, with manageable neutropenia
Pomalidomide (Pom), an oral immunomodulatory drug that augments T-cell co-stimulation, was combined with nivolumab (Nivo), an anti–PD-1 antibody, in a 3+3 Phase I dose-escalation trial in advanced virus-associated…
NCT04902443 - Trial result
Sarcoma and GIST
Cetuximab (anti-EGFR mAb) delivers 8% RECIST PRs but high SD/ATR rate in advanced chordoma
Cetuximab is a chimeric monoclonal antibody that blocks EGFR signaling; in this investigator-initiated, single-center Phase 2 trial (NCT05041127), adults with unresectable locally recurrent/metastatic chordoma (mITT…
NCT05041127 - Trial result
Sarcoma and GIST
Rogaratinib (pan-FGFR1–4 inhibitor) posts 41.7% ORR and 31.0-mo PFS in advanced SDH-deficient GIST
Rogaratinib (BAY 1163877) is an oral pan–fibroblast growth factor receptor (FGFR1–4) tyrosine kinase inhibitor intended to shut down the FGF3/FGF4→FGFR1 autocrine loop thought to be epigenetically activated in…
NCT04595747 - Trial result
Sarcoma and GIST
Bezuclastinib (selective type 1 KIT TKI) + sunitinib (type 2 KIT/VEGFR TKI) halves progression risk in 2L GIST
Bezuclastinib is an oral, selective type 1 KIT tyrosine kinase inhibitor designed to cover common KIT resistance mutations and was paired with sunitinib, a type 2 TKI, to broaden inhibition across primary + secondary…
NCT05208047
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.